ECSP13012847A - Dimaleato de 9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazolin-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, su uso como medicamento y su preparación. - Google Patents
Dimaleato de 9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazolin-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, su uso como medicamento y su preparación.Info
- Publication number
- ECSP13012847A ECSP13012847A ECSP13012847A ECSP13012847A EC SP13012847 A ECSP13012847 A EC SP13012847A EC SP13012847 A ECSP13012847 A EC SP13012847A EC SP13012847 A ECSP13012847 A EC SP13012847A
- Authority
- EC
- Ecuador
- Prior art keywords
- espiro
- iloxi
- metoxi
- undecan
- dimaleate
- Prior art date
Links
- 229940126601 medicinal product Drugs 0.000 title 1
- 206010003658 Atrial Fibrillation Diseases 0.000 abstract 1
- 230000000740 bleeding effect Effects 0.000 abstract 1
- 229960000288 dabigatran etexilate Drugs 0.000 abstract 1
- KSGXQBZTULBEEQ-UHFFFAOYSA-N dabigatran etexilate Chemical compound C1=CC(C(N)=NC(=O)OCCCCCC)=CC=C1NCC1=NC2=CC(C(=O)N(CCC(=O)OCC)C=3N=CC=CC=3)=CC=C2N1C KSGXQBZTULBEEQ-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
Abstract
Un método para prevenir el ictus en un paciente que padece fibrilación auricular, en el que el paciente no tiene factores de riesgo para acontecimientos hemorrágicos mayores, comprendiendo el método administrar al paciente 150 mg b.i.d. de etexilato de dabigatrán, opcionalmente en forma de una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11152895 | 2011-02-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP13012847A true ECSP13012847A (es) | 2014-09-30 |
Family
ID=43896655
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSP13012847 ECSP13012847A (es) | 2011-02-01 | 2013-08-21 | Dimaleato de 9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazolin-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, su uso como medicamento y su preparación. |
Country Status (23)
Country | Link |
---|---|
US (2) | US8853225B2 (es) |
EP (1) | EP2670736B1 (es) |
JP (1) | JP2014504619A (es) |
KR (1) | KR20140011330A (es) |
CN (1) | CN103608336A (es) |
AP (1) | AP3531A (es) |
AR (1) | AR085056A1 (es) |
AU (1) | AU2012213556A1 (es) |
BR (1) | BR112013019416A2 (es) |
CA (1) | CA2826193A1 (es) |
CL (1) | CL2013002031A1 (es) |
CO (1) | CO6781555A2 (es) |
EA (1) | EA023573B1 (es) |
EC (1) | ECSP13012847A (es) |
GE (1) | GEP20156423B (es) |
IL (1) | IL227534A0 (es) |
MA (1) | MA34845B1 (es) |
MX (1) | MX2013008870A (es) |
PE (1) | PE20141012A1 (es) |
SG (1) | SG192216A1 (es) |
TN (1) | TN2013000323A1 (es) |
UY (1) | UY33889A (es) |
WO (1) | WO2012104206A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2289881A1 (de) * | 2009-08-06 | 2011-03-02 | Boehringer Ingelheim International GmbH | Verfahren zur stereoselektiven Synthese bicyclischer Heterocyclen |
EA023573B1 (ru) | 2011-02-01 | 2016-06-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Дималеат 9-[4-(3-хлор-2-фторфениламино)-7-метоксихиназолин-6-илокси]-1,4-диазаспиро[5.5]ундекан-5-она, его применение в качестве лекарственного средства и его получение |
JP6105631B2 (ja) | 2012-02-09 | 2017-03-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 1,4−保護9−ヒドロキシ−5−オキソ−1,4−ジアザ−スピロ[5.5]ウンデカンの立体選択的合成方法 |
WO2014012859A1 (en) | 2012-07-19 | 2014-01-23 | Boehringer Ingelheim International Gmbh | Fumaric acid salt of 9-[4-(3-chloro-2-fluoro-phenylamino)-7-methoxy- chinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undecan-5-one, its use as medicament and the preparation thereof |
WO2015085654A1 (zh) * | 2013-12-12 | 2015-06-18 | 天津合美医药科技有限公司 | 喹唑啉衍生物 |
CN105130913A (zh) * | 2015-08-25 | 2015-12-09 | 佛山市赛维斯医药科技有限公司 | 一类多取代的苯并喹唑啉类酪氨酸激酶抑制剂及用途 |
CN105017164A (zh) * | 2015-08-25 | 2015-11-04 | 佛山市赛维斯医药科技有限公司 | 含新型苯并喹唑啉和邻位氯结构的酪氨酸激酶抑制剂及用途 |
CN109503579A (zh) * | 2018-12-17 | 2019-03-22 | 天津药明康德新药开发有限公司 | 叔丁基-1-甲基-5-氧亚基三氮杂螺[5.5]十一烷-9-甲酸基酯的制备方法 |
CN109485648A (zh) * | 2018-12-17 | 2019-03-19 | 无锡合全药业有限公司 | 叔丁基-1-甲基-5-氧亚基三氮杂螺[5.5]十一烷-8-甲酸基酯的制备方法 |
CN109608470A (zh) * | 2018-12-17 | 2019-04-12 | 上海药明康德新药开发有限公司 | 叔丁基-9-氧亚基-2,5,8-三氮杂螺[3.5]壬烷-2-甲酸基酯的合成方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200813014A (en) | 2002-03-28 | 2008-03-16 | Astrazeneca Ab | Quinazoline derivatives |
EA009300B1 (ru) * | 2002-03-30 | 2007-12-28 | Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг | 4-(n-фениламино)хиназолины/-хинолины в качестве ингибиторов тирозинкиназы |
CN101061112A (zh) | 2004-09-17 | 2007-10-24 | Osi制药公司 | 作为c-Kit原癌基因抑制剂的(螺环基酰氨基)氨基噻吩化合物 |
BRPI0619603A2 (pt) | 2005-12-12 | 2011-10-11 | Boehringer Ingelheim Int | heterociclos bicìclicos, sais fisiologicamante compatìveis, medicamentos que contêm esses compostos, bem como uso e processos para produção dos heterociclos bicìclicos |
BRPI0818687A2 (pt) | 2007-10-26 | 2017-05-02 | Japan Tobacco Inc | composto espiro, o sal deste farmaceuticamente aceitavél ou o solvato deste, composição farmacêutica, medicamento agonista de gpr40, agente promotor da secreção de insulina ou um agente hipoglicêmico, uso do composto espíro, o sal deste farmaceuticamente aceitavél ou o solvato deste, e, métodos para a ativação de gpr40, para promover secreção de insulina ou diminuir o nível de glicose sanguínea, e para tratar ou prevenir uma doença. |
WO2009098061A1 (de) * | 2008-02-07 | 2009-08-13 | Boehringer Ingelheim International Gmbh | Spirocyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
US8629153B2 (en) * | 2008-09-03 | 2014-01-14 | Boehringer Ingelheim International Gmbh | Use of quinazoline derivatives for the treatment of viral diseases |
EP2289881A1 (de) * | 2009-08-06 | 2011-03-02 | Boehringer Ingelheim International GmbH | Verfahren zur stereoselektiven Synthese bicyclischer Heterocyclen |
EA023573B1 (ru) | 2011-02-01 | 2016-06-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Дималеат 9-[4-(3-хлор-2-фторфениламино)-7-метоксихиназолин-6-илокси]-1,4-диазаспиро[5.5]ундекан-5-она, его применение в качестве лекарственного средства и его получение |
-
2012
- 2012-01-27 EA EA201300872A patent/EA023573B1/ru not_active IP Right Cessation
- 2012-01-27 MA MA36143A patent/MA34845B1/fr unknown
- 2012-01-27 WO PCT/EP2012/051298 patent/WO2012104206A1/de active Application Filing
- 2012-01-27 BR BR112013019416A patent/BR112013019416A2/pt not_active IP Right Cessation
- 2012-01-27 EP EP12702480.0A patent/EP2670736B1/de active Active
- 2012-01-27 GE GEAP201213210A patent/GEP20156423B/en unknown
- 2012-01-27 AU AU2012213556A patent/AU2012213556A1/en not_active Abandoned
- 2012-01-27 CA CA2826193A patent/CA2826193A1/en not_active Abandoned
- 2012-01-27 MX MX2013008870A patent/MX2013008870A/es not_active Application Discontinuation
- 2012-01-27 JP JP2013552160A patent/JP2014504619A/ja active Pending
- 2012-01-27 US US13/359,807 patent/US8853225B2/en active Active
- 2012-01-27 PE PE2013001723A patent/PE20141012A1/es not_active Application Discontinuation
- 2012-01-27 CN CN201280016804.XA patent/CN103608336A/zh active Pending
- 2012-01-27 AP AP2013006989A patent/AP3531A/xx active
- 2012-01-27 SG SG2013057880A patent/SG192216A1/en unknown
- 2012-01-27 KR KR1020137023135A patent/KR20140011330A/ko not_active Application Discontinuation
- 2012-01-31 AR ARP120100317A patent/AR085056A1/es unknown
- 2012-02-01 UY UY0001033889A patent/UY33889A/es unknown
-
2013
- 2013-07-12 CL CL2013002031A patent/CL2013002031A1/es unknown
- 2013-07-18 IL IL227534A patent/IL227534A0/en unknown
- 2013-07-29 TN TNP2013000323A patent/TN2013000323A1/fr unknown
- 2013-08-01 CO CO13183058A patent/CO6781555A2/es not_active Application Discontinuation
- 2013-08-21 EC ECSP13012847 patent/ECSP13012847A/es unknown
-
2014
- 2014-08-28 US US14/471,147 patent/US8906931B1/en active Active
Also Published As
Publication number | Publication date |
---|---|
NZ613917A (en) | 2015-08-28 |
CA2826193A1 (en) | 2012-08-09 |
KR20140011330A (ko) | 2014-01-28 |
US8853225B2 (en) | 2014-10-07 |
EP2670736B1 (de) | 2017-03-15 |
IL227534A0 (en) | 2013-09-30 |
CN103608336A (zh) | 2014-02-26 |
EA023573B1 (ru) | 2016-06-30 |
AP2013006989A0 (en) | 2013-07-31 |
US8906931B1 (en) | 2014-12-09 |
GEP20156423B (en) | 2016-01-11 |
EA201300872A1 (ru) | 2014-01-30 |
UY33889A (es) | 2012-08-31 |
EP2670736A1 (de) | 2013-12-11 |
MA34845B1 (fr) | 2014-01-02 |
AU2012213556A1 (en) | 2013-08-22 |
AR085056A1 (es) | 2013-08-07 |
CO6781555A2 (es) | 2013-10-31 |
SG192216A1 (en) | 2013-09-30 |
PE20141012A1 (es) | 2014-09-10 |
US20140371226A1 (en) | 2014-12-18 |
CL2013002031A1 (es) | 2013-12-27 |
BR112013019416A2 (pt) | 2019-09-24 |
WO2012104206A1 (de) | 2012-08-09 |
TN2013000323A1 (en) | 2015-01-20 |
MX2013008870A (es) | 2013-08-14 |
US20130030003A1 (en) | 2013-01-31 |
AP3531A (en) | 2016-01-13 |
WO2012104206A9 (de) | 2013-11-21 |
JP2014504619A (ja) | 2014-02-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP13012847A (es) | Dimaleato de 9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazolin-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, su uso como medicamento y su preparación. | |
CR20160205A (es) | Inhibidores de kras g12c | |
BR112015020389A8 (pt) | compostos carbazol úteis como inibidores de bromodomínio, seu uso, bem como composição e produto farmacêuticos compreendendo os mesmos | |
PE20150161A1 (es) | Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple | |
SV2015005115A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
ECSP15008695A (es) | Combinaciones farmacéuticas que comprenden un inhibidor de b-raf, un inhibidor de egfr y opcionalmente un inhibidor de pi3k-alfa | |
PE20221914A1 (es) | Compuestos de benzaldehido sustituidos y metodos para su uso en incrementar la oxigenacion del tejido | |
EA201491285A1 (ru) | Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты | |
AR084691A1 (es) | Formulacion de uso topico para un inhibidor de jak y metodo para tratar trastorno de la piel | |
AR089578A1 (es) | Composiciones, metodos para tratar el virus de la hepatitis c y proceso de preparacion | |
DOP2014000008A (es) | 4-imidazopiridazina-1-il-benzamidas y 4-imidazotriazina-1-il-benzamidas como inhibidores de btk | |
IN2014DN09434A (es) | ||
GT201300308A (es) | Combinación de panobinostat y ruxolitinib en el tratamiento del cancer tal como una neoplasia mieloproliferativa | |
CO7310528A2 (es) | Composición farmacéutica recubierta que contiene regorafenib | |
CL2011000798A1 (es) | Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular. | |
CO6382133A2 (es) | Metodo para tratar o prevenir la trombosis usando etexilato de dabigatran o una sal del mismo con una eficacia mejorada sobre la terapia con warfarina convencional | |
NI201600048A (es) | Formulaciones de (s)- 3- (4-((4-(morfolinometil) bencil)oxi)-1-oxoisoindolin-2-il) piperidin-2, 6-diona | |
CO6561789A2 (es) | Método de tratamiento | |
AR097619A1 (es) | Uso de inhibidores de acetil-coa carboxilasa para tratar acné vulgaris | |
CL2015001615A1 (es) | Una composicion farmaceutica que comprende vortioxetina y donepezilo junto con un excipiente farmaceuticamente aceptable; y su uso para el tratamiento de disfuncion cognitiva, demencia en la enfermedad de alzheimer, disfuncion cognitiva asociada a la depresion y a la esquizofrenia, entre otras enfermedades. | |
CL2013003700A1 (es) | Composicion farmaceutica oftalmologica topica que comprende regorafenib, el cual se encuentra suspendido en un vehiculo farmaceuticamente aceptable; procedimiento de fabricacion y su uso para tratar o prevenir un trastorno oftalmologico. | |
AR088204A1 (es) | Medicamentos para el tratamiento de la rinitis alergica que comprenden un antagonista de pgd2 y un antagonista de histamina | |
AR084882A1 (es) | Compuesto de 1-azabiciclo[2.2.2]octano y usos para el tratamiento de esquizofrenia | |
AR088497A1 (es) | Composiciones farmaceuticas de combinaciones de inhibidores de la dipeptidil peptidasa 4 con atorvastatina | |
MX348723B (es) | Combinaciones de solifenacina y estimulantes salivales para el tratamiento de la vejiga hiperactiva. |